Sandoz launches generic Revlimid in 19 countries in Europe

Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, it has girded for the day the multiple myeloma superstar would face generics. In many European countries, that day is here. On Friday, Novartis' Sandoz revealed that it has launched its generic version of the medicine in 19 countries in Europe. German generics maker Stada Arzneimittel also has launched its Revlimid generic in Europe, according to reports. Lenalidomide will provide cost savings for patients, Sandoz said, expanding treatment options for those with multiple myeloma, previously treated follicular lymphoma or relapsed or refractory mantel cell lymphoma patients. Sandoz, the global generics division of Novartis, is the largest generics producer in Europe. The division of the Swiss pharma giant accounted for $9.8 billion in worldwide sales last year. Last September, Sandoz launched its generic lenalidomide in Canada. Meanwhile, the first Revlimid generics are scheduled to reach the huge United States market next month. The drug generated $12.8 billion for BMS last year, the company recently reported. With the flood of incoming competition, BMS expects sales of Revlimid to drop to between $9.5 billion and $10 billion this year. Since Revlimid was originally approved in 2006, Celgene worked hard to stave off competition through court battles and settlements. In certain smaller European markets, Alvogen managed to launch its Revlimid generic back in 2019.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!